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Summary: Administration of a single dose of jD-galactosamine to rats causes time-dependent, biphasic changes of
total glycosaminoglycan synthesis in liver. A rapidly occurring inhibition is followed by a significantly enhanced
0> 2 fold) production of 35S-labeled glycosaminoglycans in later stages of injury. Degree and duration of the in-
hibitory phase are dose-dependent; 50% inhibition is reached at 80 mg/kg and maximum inhibition (nearly 80%) at
about 300 mg/kg body weight 2 h after injection of Z)-galactosamine.
The hepatötoxin impairs preferentially the production of heparan sulfate, whereas that of chondroitin sulfate and
dermatan sulfate is diminished only slightly and for a rather short period of time. The synthesis of the latter, however,
is more stimulated than that of heparan sulfate in later stages of injury.
The specific radioactivity of 35S-labeled 3'-phosphoadenosine-5'-phosphosulfate (PAPS) did not change significantly
during the course of acute liver damage.
Glycosaminoglycan synthesis in regenerating liver was nearly unaffected by D-galactosamine. Uridine at the dose
applied partially reversed Agdactosamine-inhibited synthesis of proteoheparan sulfate.
In accordance with the labeling studies the content of glucosamine^containing glycosaminoglycans in treated liver
decreased, whereas that of galactosamine-cöntainiiig glycosaminoglycans slightly increased, resulting in a nearly 50%
reduction of the glucosamine/galactosamine ratio 5 h after administration of Z)-galactosamine. Ion exchange Chromato-
graphie studies of 35S4abeled specific types of glycosaminoglycans from normal and galactosamine-injured liver
revealed only minor structural differences.
Synthese der Leberglykosaminoglykane in den Frühstadien der Galaktosamin-Hepatitis: Einer raschen Erniedrigung
des Heparansulfates folgt eine Erhöhung von Chondroitinsulfat und Dermatansulfat
Zusammenfassung: Eine Einzeldpsis von D-Galaktösamin erzeugt in der Rattenleber zeitabhängige, biphasische Ver-
änderungen der Glykosaminoglykansynthese. Eine sofort eintretende Hemmung wird gefolgt von einer signifikant
erhöhten (über 2fäch) Produktion 35S-marJaerter Glykosaminoglykane in späteren Stadien der Schädigung. Grad und
Dauer der inhibitorischen Phase sind dosisabhängig; 50% der Hemmung tritt bei 80 mg/kg und maximale Hemmung
(nahezu 80%) bei etwa 300 mg/kg Körpergewicht 2 Stunden nach Verabreichung von £-Galaktosamin ein. Das hepato-
töxische Z^Gdaktosamin beeinträchtigt vorzugsweise die Produktion von Heparansulfat, wohingegen die Synthese von
Chondroitinsulfat und Dermatansulfat nur geringgradig und für einen kurzen Zeitraum vermindert ist. Die Bildung der
letztgenannten Glykosaminoglykane wird jedoch in späteren Stadien der Schädigung stärker als die von Heparansulfat
stimuliert.
Die spezifische Radioaktivität von 35S-markiertem 3'-Phosphoadenosin-5'-phosphosulfat (PAPS) verändert sich im
Verlauf der akuten Leberschädigung nicht signifikant.
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Die Glykosaminoglykansynthese in der regenerierenden Leber wird durch D-Galaktosamin nicht beeinflußt, Uridin in
der angegebenen Dosierung führt zu einer partiellen Reversibilität derD-Galaktosamin bedingten Hemmung der Syn-
these von Proteoheparansulfat.
In Übereinstimmung mit den Markierungsstudien nimmt die Konzentration Glucosamin-enthaltender Glykosamino-
glykane in der behandelten Leber ab, wohingegen die der Galaktosamin-enthaltenden Glykosaminoglykane gering-
gradig ansteigt. Dies fuhrt zu einer Reduktion des Glucosamin/Galaktosamin Verhältnisses um nahezu 50% 5 h nach
Gabe von £)-Galaktosamin.
lonenaustauschchromatographische Untersuchungen 35S-markierter spezifischer Typen der Glykosaminoglykane von
normalen und Galaktosamin-geschädigten Lebern ließen nur geringe strukturelle Unterschiede erkennen.
Introduction
Administration of £)(+)-galactosamine to rats causes
acute liver damage, which resembles biochemically
and morphologically human viral hepatitis (1-5). The
primary pathobiochemical lesions initiated by the hepa-
totoxic D-galactosamine have been studied in detail and
found to be an intracellular depletion of uridine phos-
phates and UDP-sugars accompanied by an accumulation
of UDP-hexosamines (6-9). Much less is known, how-
ever, about the molecular mechanisms of the subsequent
events, such as the inhibition of macromolecular syn-
theses, and hence about their contribution to the death
of the hepatocyte. Recently, the liver cell plasma mem-
brane has been identified as the key target organelle of
galactosamine-hepatotoxicity (10—13). It is known that
several types of proteogjycans, in particular proteo-
heparan sulfate, are intimately associated with the
surface of the hepato-cellular membranes (14-17).
Although the functions of the cell coat proteoglycans
are only speculative at present their ubiquity, high
metabolic rate and structural heterogeneity suggest
a significant role in normal cellular metabolism (18,
19). Conversely, perturbations of the synthesis of
proteoheparan sulfate during the course of galactos-
amine-induced liver damage migjit be meaningful for
the pathogenesis of hepatocellular necrosis. This
prompted us to study the hepatic synthesis of total
and specific types of glycosaminoglycans during the
early phase of galactosamine-provoked liver injury and
in galactosamine-refractory regenerating liver (20).
Materials and Methods
Materials
D-Galactosamine-HCl was obtained from C. Roth OHG, Karls-
ruhe; uridine (crystalline, Sigma grade) from Sigma Chemical
Company, Munich; chondroitin AC (EC 4.2.2.5) and chondroitin
ABC (EC 4.2.2.4) lyases were from Seikagaku Kogyo Comp.,
Tokyo, Japan; papain (EC 3.4.22.2, crystalline suspension,
30 U/mg orotein) was from Boehiinger Mannheim GmbH;
sodium ("S) sulfate (carrier free) and 3'-phosphoadenosine-
5'-phosphosulfate (tetrasodium salt, 3'-[3sS], 10.73 TBq/mol
(0.29 Ci/mmol), lot. 1255-263) were from New England
Nuclear Corp., Boston, USA; harmol-HCl (lot. 63 C-1330) was
from Sigma Chemical Comp., Munich, FRG and thin-layer
chromatography plates (CEL 300-25) were purchased from
Macherey-Nagel Co., Duren, FRG.
Treatment of rats
Male Sprague-Dawley rats (Zentralinstitut für Versuchstiere,
Hannover, FRG) weighing 260 ± 30 g had free access to a
standard rat diet and water throughput the experimental
period. They were injected intraperitoneally between 8:00
and 10:00 a.m. with variable amounts of D-galactosamine-HCl,
freshly dissolved in 0.154 mol/1 of NaCl. The precise doses are
given in the legends of the appropriate figures and tables.
Control rats received an equal volume of NaCl alone. Uridine,
dissolved in isotonic NaCl, was administered intraperitoneally
in ä dose of 272 mg/kg body weight. Partial hepatectomy (21)
was performed under light ether anaesthesia between 8:30
and 10:00 a.m.; control animals were operated similarly but
their livers were replaced in the abdomen after being exposed
for about 30 s (sham-operated rats). Thirty min prior to decapi-
tation the rats received intraperitoneally 3.7 MBq of [3SSJ sulfate
dissolved in 0.2 ml of 0.154 mol/1 of NaCl.
Incorporation of [3*S\sulfate into total glycosaminoglycans
After decapitation the livers were quickly removed, minced and
carefully freed of blood in ice-cold buffer (0.05 mol/1 Tris-
HC1, pH 7.6 (20 °C), 0.08 mol/1 KC1, 0.0125 mol/1 MgCl2,
0.25 mol/1 sucrose). The tissue was defatted by repeated wash-
ings each with 10 volumes of cold acetone, chlproform-methanol
(volumes, 200 ml + 100 ml), and ethanol-ether (volumes,
300 ml + 100 ml). Subsequently it was dried for 24 h at 60 °C,
weighed and proteolysed for 2 days in papain-buffer (22) at
65 °C with two separate additions of 5 and 2.5 mg of papain,
respectively. The digestion was terminated with 50 g/1 of tri-
chloroacetic acid and the supernatant obtained after centrifu-
gation (2000£, 15 min, 0 °C) neutralized and dialysed at 4 °C
against 50 volumes of 0.03 mol/1 of NaCL After addition of un-
labeled glycosaminoglycans as carrier the radiolabeled glycos-
aminoglycans were precipitated with eetylpyridinium chloride
as described previously (23, 24). The final sediment containing
total glycosaminoglycans was dissolved in water and a portion
was counted in a liquid scintillation spectrometer with an
efficiency of 0.81 for 35S.
Incorporation of [3SS] sulfate into specific types of glycos-
aminoglycans
35S-labeled glycosaminoglycans were subjected to enzymatic
analysis with chondroitin AC and ABC lyases and to degrada-
tion with nitrous acid. The details of the procedures and the *
calculation of the results have been reported elsewhere (23).
The amount of.[3S S J sulfate incorporated into total and indivi-
dual glycosaminoglycans is referred to liver dry weight.
Determinations of concentration and specific radioactivity of
S'-phosphoadenosine-S'-phosphosulfate (PAPS) in rat liver
Concentrations and specific activity of PAPS in normal and
galactosamine-injured liver were determined by a recently
developed fluorimetric assay (25). Immediately after decapi-
tation a portion of the 3^S-labeled liver was frozen and
pulverized in liquid nitrogen, of which l g was denatured in
2 ml of boiling buffer (0.5 mol/1 glycine, pH 9.2 (20 °C).
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After homogenization and centrifugation (30 min, 15,000£,
2 °C) the supernatant containing PAPS was extracted with
chloroform. The water phase was incubated for l h at 37 °C
with harmol in the presence of 178 000 g dog liver super-
natant. After termination and chloroform extraction harmol
sulfate was separated from harmol by thin-layer chromato-
graphy (25) giving Rf values of 0.5 and 0.75 respectively.
UV-visible spots containing harmol sulfate were scraped from
the plate and desorbed with 0.1 mol/1 HCl. In the cluate radio-
activity was measured and concentration of harmol was deter-
mined fluorimetrically (excitation 315 nm, emission above
400 nm) using an Eppendorf 1101 M photometer with fluores-
cence equipment. A calibration curve ranging from 2 to 200
nmol/1 was established for harmol. The intra-assay CV was about
15% and the recovery of authentic PAP[35SJ was about 0.8.
Ion exchange chromatography of 3SS-labeIed liver glycos-
aminoglycans
Total glycosaminoglycans from liver of normal and galactos-
amine-treated rats isolated as outlined above were Chromato-
graph ed on columns (0.6 X 13 cm) of Dowex 1 X 2 (Cf, 200-
400 mesh) by stepwise elution with each 50 ml of 0.5, 1.0,
1.25, 2.0, and 3.0 mol/1 of NaCI. The eluates were dialysed
against water, lyophylised and subjected to enzymatic and
chemical identification as described above.
Determination of hexosamines in total hepatic glycosamino-
glycans
£>· Galactosamine-treated and untreated (control) rat livers were
defatted, dried, weighed, and proteolysed as described above.
The proteolysate was dialysed against 0.5 mol/1 of NaCI and
applied to a column (0.6 X 13 cm) of Dowex 1 X 2 equi-
librated with 0.5 mol/1 of NaCI. After extensive washing the
column was eluted with 30 ml of 3.0 mol/l of NaCI and the
eluate was concentrated, dialysed against 0.03 mol/1 of NaCI
and precipitated with cetylpyridinium chloride (23). The preci-
pitate was hydrolyzed in 3 mol/1 of HCl for 15 h at 105 °C
and for quantitation of hexosamines applied to a Biotronik
Amino Acid Analyzer LC 2000 equipped with a fluorescence
detector BT 6630.
Results
Effect of D-galactosamine on the incorporation of
[3SS]sulfate into total and specific glycosaminoglycans
of liver
Normal rat liver incorporates very rapidly but at marked-
ly different rates intraperitoneally applied [35S]sulfate
into the various types of glycosaminoglycans; 0.8 of the
total glycosaminoglycan-associated radioactivity (1.4
kfiq/g liver dry weight · 0.5 h"1) is found in nitrous acid-
labile material (heparan sulfate) whereas only 0.16 and
0.04 of total activity are linked to dermatan sulfate and
chondroitin sulfate, respectively.
The administration of 700 mg/kg body weight of D-
galactosamine to rats results in a prompt and severe
inhibition of [35S] sulfate incorporation into total
hepatic glycosaminoglycans (fig. 1). As early as 30 min
after application of the hepatotoxic jD-galactosamine
the incorporation is diminished by more than 80%.
Thereafter the production of labeled glycosamino-
glycans increases gradually, reaching 50% inhibition
at about 12 h and control values at about 22 h after
onset of treatment, 2 days after injection of ^ -galactos-
amine the incorporation of [3sS)sulfate into liver
glycosaminoglycans is significantly stimulated.
The inhibition of total glycosaminoglycan synthesis
by £>-galactosamine follows a dose-response curve
(fig. 2) which shows 50% inhibition at 80 mg/kg and
maximum inhibition (about 80%) at about 300 mg/kg
body weight.
Further studies were performed to analyse the production
of 35S-labeled specific types of glycosaminoglycans in
response to galactosamine-induced hepatic damage.
Figure 1 demonstrates that the hepatotoxic D-galactos-
amine greatly diminished the formation of heparan
[35S]sulfate between 0.5 and 6 h after administration.
During this period heparan sulfate production was only
0.05 ofthat of untreated rats; it increased to control
values 40 h after the beginning of the treatment. In con-
trast to heparan sulfate the labeling of chondroitin sul-
fate and dermatan sulfate was reduced only slightly and
for a rather short period of time (between 0.5 and 1 h).
It is of interest that the rate of chondroitin [35S]sulfate
"5 2S
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Fig. 1. The synthesis of 35S-labeIed glycosaminoglycans in liver
treated for various times with £>-galactosamine.
Rats were injected with 700 mg/kg body weight or a
similar volume of 0.154 mol/1 of NaCI (control) and
received at the times indicated 3.7 MBq of [3SS1 sulfate
30 min before decapitation. The livers were removed,
defatted, dried, weighed and proteolysed in order to
isolate total glycosaminoglycan-associated radioactivity.
The incorporation of radioactivity into specific types of
sulfated glycosaminoglycans was assayed by chemical
(heparan sulfate) and enzymatic procedures (chondroitin
sulfate, dermatan sulfate). The amount of glycosamino-
glycan-bound [3SSlsulfate was referred to defatted liver
diy weight. The incorporation of the isotope into total
(a) and specific glycosaminoglycans (b, ·—· chondroitin
sulfate, ï—ï dermatan sulfate, ·—· heparan sulfate) of
galactosamine-treated liver is expressed as fraction of in-
corporation into glycosaminoglycans of the appropriate
control livers. Each value represents the mean ± S.D. of 3
to 4 independent experiments.
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Fig. 2. Dose-response curve of the effect of ^-galactosamine on the
incorporation of (35S]sulfate into total hepatic glycos-
aminoglycans. Rats received intraperitoneally variable
amounts of /)-galactosamine. 2 h later and 30 min before
decapitation 3.7 MBq of (35S] sulfate was administered to
each animal. Unfractionated labeled glycosaminoglycans
were isolated from the liver as described in the legend of
fig. 1. The values are the mean of duplicate determinations.
formation began to increase 3 h after initiation of liver
damage, reaching greatly elevated levels after 2 days.
A similar time-course of [35S]sulfate incorporation was
observed for dermatan sulfate (fig. Ib).
Concentration and specific radioactivity of liver 3'-phos-
pho-adenosine-5'-phosphosulfate (PAPS) in response to
D-galactosamine
The concentration of PAPS in normal rat liver was found
to be 21.1 ± 2.6 nmol/g wet weight (fig. 3). It increased,
during the phase of maximal inhibition of heparan sulfate
production, up to 25 nmol/g liver wet weight, but was
greatly diminished in the later stages of injury when the
production of chondroitin [35S]sulfate and dermatan
[35S] sulfate was accelerated. The specific radioactivity of
PAP[35S] in liver, however, did not change significantly
during the course of acute liver damage. Therefore,
changes in the rates of incorporation of the isotope into
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Fig. 3, Concentration and specific radioactivity of 3'-phospho-
adenosine-5'^phosphosulfate in rät liver following
administration of Z)-galactosamine.
Rats were injected with 700 mg/kg body weight of
D-galactosamine and received at the times indicated
30 min before decapitation 3,7 MBq of [35Sj sulfate.
Portions of the liver were frozen in liquid nitrogen,
weighed and applied to fluorimetric quantitation and
determination of specific activity of PAPSi The mean
values ± S.D. of 3 to 4 independent experiments are
given.
the glycosaminoglycans obviously do not reflect varia-
tions in the specific radioactivity of activated sulfate.
Effect of D-galactosamine on the incorporation of
[3SS]sulfate into glycosaminoglycans of regenerating
liver
The synthesis of [35S]glycosaminoglycans in prolifer-
ating rat liver two days after partial hepatectomy is only
moderately inhibited by D-galactosamine (tab. 1). In
sham-operated livers, however, the incorporation of
the isotope into total glycosaminoglycans decreases
from 3.3 to 2.3 kBq/g liver dry weight. The data
summarized in table 1 show that the production of
Tab. L The effect of D-galactosamine on the incorporation of [35Slsulfate into specific glycosaminoglycans of regenerating liver.
Rats were partially hepatectomized or sham-operated 2 days before intraperitoneal administration of 200 mg/kg body weight.
Control rats received NaCl instead of /)-galactosamine. 6 h after application of .D-galactosamine and 30 min before decapitation
37 MBq of (35SJsulfate were injected. The incorporation of the isotope into individual glycosaminoglycans was determined as
outlined in fig. 1. The number of rats is given in parentheses.
Treatment of rats Incorporation of [3SS]sulfate into specific glycosaminoglycans
[kBq/g liver dry weight!
Heparan sulfate * Dermatan sulfate Chondroitin sulfate
Partial hepatectomy
(n = 6)
Sham-operated
(n = 6)
NaCl
Galactosamine
NaCl
Galactosamine
3.02 ± 0.43
2.74 ± 0.86
2.25 ±0,16
0.76 ±0.19
1.05 ± 0.15
1.02 ± 0.02
0.66 ± 0.05
0.76 ± 0;02
. 0.33±0;04
0.33 ± 0.02
0.23 ± 0.03
0,49 ± 0.0$
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heparan [3S SJsulfate is reduced by less than 10% in
regenerating liver 6 h after application of /)-galactos-
amine, but in treated, sham-operated animals the in-
corporation of [35SJsulfate into this type of glycos-
aminoglycans is diminished by about 70%. Further-
more, the labeling of chondroitin sulfate and dermatan
sulfate in response to Z)-galactosamine is quite different
in proliferating and non-proliferating livers. In the
latter the radioactivity associated with chondroitin
sulfate and dermatan sulfate increases, whereas in
regenerating liver galactosamine was without effect
on the rate of incorporation of [35S] sulfate into both
types of glycosaminoglycans. Taken together the results
demonstrate that under the experimental conditions
described the synthesis of [35S]glycosaminoglycans
in regenerating rat liver is not inhibited by D-galactos-
amine.
Effect of undine on galactosamine-induced depression
of [3S S]sulfate incorporation into liver glycosamino-
glycans
Another way to counteract the effect of D-galactos-
amine on hepatocellular metabolism is provided by the
administration of undine (6). Two repeated applica-
tions of equimolar amounts of uridine to galactosamine-
treated rats result in a partial reversibility of the inhi-
bition of glycosaminoglycan formation observed with
£>-galactosamine alone. The incorporation of [3SSJ-
sulfate into total glycosaminoglycans increases from
0.24 to 0.55 of control, and that into heparan sulfate
from 0.12 to 0.45 of control (tab. 2). The application
of uridine alone was without significant effects on the
formation of total and specific 35S-labeled glycosamino-
glycans (tab. 2). It should be noted that uridine was
without effect on galactosamine-induced inhibition of
[35S]glycosaminoglycans synthesis when both com-
pounds were applied simultaneously for shorter periods
of time than 3 h. Furthermore, under these conditions
uridine alone caused a significant depression of liver
[35S]glycosaminoglycan formation (results not shown).
Ion exchange Chromatographie distribution of
[3S S]glycosaminoglycans from normal and galactosamine-
treated liver
To detect gross structural differences between [35SJ-
glycosaminoglycans isolated from normal and galactos-
amine-treated rat liver, respectively, their elution pro-
files on Dowex 1 X 2 were recorded (fig. 4). In general,
unfractionated glycosaminoglycans obtained from rat
liver treated for 5 h with 700 mg/kg of D-galactosamine
tended to elute at higher ionic strength from Dowex
than those from normal liver. With 1.25 mol/1 of NaCl
0.4 and 0.62 of total glycosaminoglycan-associated
radioactivity of injured and untreated liver, respectively,
were recovered in the effluent. The elution profile of
nitrous acid-labile glycosaminoglycans, which are the
predominant type in liver, was similar for both injured
and normal rat liver up to 1.5 mol/1 of NaCl. At 2.0 mol/1
of NaCl, however, about 0.2 of heparan [3S SJsulfate from
normal liver and less than 0.02 from treated liver were
desorbed from the column. As shown in figure 4 further
differences were observed for dermatan [35SJsulfate at
1.5 mol/1 and for chondroitin [3SS]sulfate at 1.25 and
2.0 mol/1 of NaCl.
Concentration of glucosamine- and galactosamine-
containingglycosaminoglycans in D-galactosamine-
treated liver
The foregoing experiments showed that soon after
application of the hepatotoxic Z)-galactosamine pre-
dominant inhibitory effect is on the incorporat on of
[3SSJsulfate into heparan sulfate, whereas that into
chondroitin sulfate and dermatan sulfate is only slightly
impaired. Consequently, the ratio of concentration of
glucosamine- to galactosamine-containing glycosamino-
glycans should decrease in the early phase of galactos-
amino-induced liver damage. The results presented in
table 3 verify that 5 h after administration of the drug
the glucosamine/galactosamine ratio in total hepatic
glycosaminoglycans is decreased by about 50% due to
Tab. 2. Effect of uridine on the Z^alactosamine-induced inhibition of the incorporation of [35S]sulfate into glycosaminoglycans of
Rats received simultaneously 200 mg/kg body weight and an equimolar amount of uridine (272 mg/kg) or a similar volume of
Nad (1. treatment). The same dose of uridine or an identical volume of NaCl was reapplied 3 h later (2. treatment). 3 h after
the last injection and 30 min before decapitation 37 MBq of [3SS]sulfate were given to the rats. The incorporation of the isotope
into the various types of glycosaminoglycans was assayed as described in fig. 1. The data are the mean ± S.D. of 3 separate ex-
periments.
1. Treatment 2. Treatment Incorporation of [3SS]sulfate into specific glycosaminoglycans[kBq/g liver dry weight]
Heparan sulfate Dermatan sulfate Chondroitin sulfate
NaCl/NaCl
Naa/uridine
D-Galactosamine/saline
D-Galacto samine/uridine
Nad
Uridine
NaCl
Uridine
1.59 ± 0.09
1.78 ±0.16 .
0.19 ± 0.04
0.72 ±0.1 6
0.37 ± 0.03
. 0.35 ± 0.04
0.24 ± 0.09
0.27 ± 0.09
0.03 ± 0.01
0.04 ± 0.01
0.04 ± 0.02
0.07 ± 0.02
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Fig. 4, Ion-exchange chromatography of [3SS]glycosaminogly-
cans from normal and galactosamine-injured liver.
Rats were treated with D-galactosamine, 700 nig/kg body
weight or a similar volume of saline (control). 5 h later
each animal received 3.7 MBq of [35S)sulfate and was
sacrificed 30 min thereafter. Total glycosaminoglycans
were isolated from the liver and applied to a column of
Dowex 1 X 2 , which was eluted with a gradient of step-
wise increasing concentration of Nad. Each fraction of
the effluent was subjected to chemical and enzymatic
analysis to quantitate the specific types of glycosamino-
glycans. Their relative distribution among the various por-
tions expressed as fraction of total specific glycosamino-
glycan was calculated. Because of low radioactivity the
fractions eluted with 1.0 and 3.0 mol/i of NaCl were riot
identified. The elution profiles of labeled unfractionated
glycosaminoglycans (a), heparan sulfate (b), dermatan
sulfate (c), and chondroitin sulfate (d) from galactosamine
treated (·—·) and control rat liver (·—·) are shown.
Tab. 3. Concentration of glycosamihoglycan-bound glucos-
amine and galactosamine in normal and D-galactosamine-
treated rat liver.
Rats were treated for 5 h with 700 mg/kg body weight or
with a similar volume of NaCL
The defatted livers were proteolysed, precipitated with
trichlproacetic acid and the neutralized supernatant was
applied to a columun of Dowex 1 X 2 .
The uronic aeid^positive material eluting between 0.5 and
3.0 mo 1/1 of NaCl was precipitated with cetyl-pyridinium
chloride, hydrolysed and submitted to quantitative deter-
mination of hexosamines by liquid column chromato-
graphy. The results represent the mean ± S.D. of 3 experi-
ments in each group.
Treatment Concentration of
hexosamines in liver
[nmol/g defatted liver]
Glucosamine Galactosamine
Glucosamine/
galactosamine
NaCl 110± 9 60 ± 6 1.8
£>-Galactosamine 74 ± 17 75 ± 5 1.0
a depression of ghicosamine- and a slight increase of
galactosamine-containing glycosaminoglycans. In later
stages of liver injury even more pronounced changes
of this ratio were observed (not shown).
Discussion
The synthesis of the various types of glycosaminoglycans
in normal but not in regenerating rat liver is differently
inhibited by D-galactosamine. Marked uridylate deficien-
cy, which is the primary effect of D-galactosamine in
resting liver (20), does not occur in regenerating liver,
mainly because of accelerated de novo synthesis of
pyrimidine (26). Pretreatment of the rats with uridine
resulted in a partial reversibility of the inhibition. Since
uridine administered alone for shorter periods than 3 h
before decapitation also impaired the incorporation of
[35S]sulfate into liver glycosaminoglycans the dose
scheme described in table 2 was chosen. It might, how-
ever, not be optimal (e.g. rather low dose of uridine
(3)), for a complete reversion of the galactosamine effect
on liver glycosaminoglycan synthesis.
The molecular mechanisms underlying the observed
inhibition of proteoglycan synthesis in the very early
phase of galactosamine-provoked liver damage are not
yet clear. As in the case of diminished glycoprqtein
synthesis (27) it is difficult to differentiate between
inhibition of synthesis of the core protein and the poly-
saccharide chain moiety. The use of derivatives of -
i)-xyloside (28), an exogenous acceptor of glycos-
aminoglycan synthesis, might give an indication of
the level at which the depression of proteoglycan syn-
thesis is taking place. A selective impairment of the
carbohydrate sulfation, however, seems unlikely since
the concentration of S'-phosphoadenosine-S'^ phospho-
sulfate is not diminished during the phase of maximum
J. Clin. Chem.ainJBiochem. / Vol. 19,1981 / No. 6
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inhibited heparan sulfate production; the pattern of
elution of heparan sulfate from Dowex is similar for
the material from normal and galactosamine treated
liver; in parallel with the reduction of [35S] sulfate incor-
poration there was a reduction of glucosamine-con-
taining glycosaminoglycans. Thus, [35S] sulfate incor-
poration is probably a true reflection of glycosamino-
glycan chain synthesis.
The question whether the increase in UDP-glucosamine
and UDP-galactosamine in£>-galactosamine treated liver
(3) leads to incorporation of non N-acetylated, unnatural
amino sugars similar to that in glycogen (aminoglycogen)
(29, 30) remains to be answered.
The rapidly occurring, long-lasting and strong inhibition
of the formation of proteoheparan sulfate contrasts with
the rather transient and slight depression of the produc- .
tion of the galactosamine containing glycosaminoglycans.
This might be a consequence of their different metabolic
turnover, being highest for proteoheparan sulfate (14), and
their different cellular sites of synthesis. The hepatocyte
as the major if not the exclusive heparan sulfate producing
cell type in liver (14, 16, 31) is sensitive to Z)-galactos-
amine, whereas v. Kupffer cells are not target cells for
galactosamine-induced uridylate trapping (32). Although
it has not been shown before that isolated sinusoidal cells
are capable of synthesizing chondroitin sulfate and der-
matan sulfate in significant amounts, our results would
be in agreement with this assumption. Alternatively, the
almost galactosamine-refractory synthesis of chondroitin
sulfate and dermatan sulfate in liver might be due to
synthesis in non-hepatic cells, e.g. cellular components
of the blood. The greatly exaggerated synthesis of
galactosamine-containing glycosaminoglycans in
later stages of injury thus might be due to the large
accumulation of inflammatory cells in the paren-
chyma (2), of which polymorphonuclear leukocytes
and monocytes were shown to synthesize predominantly
chondroitin sulfate and dermatan sulfate, respectively
(33). Unspecific, inflammatory reactions might also
be responsible for the observed increase in the pro-
portions of synthesized chondroitin sulfate and dermatan
sulfate in sham-operated livers (tab. 1) as compared with
saline-injected control rat livers (tab. 2). Undoubtedly,
the variable contribution of inflammatory blood cells
to the metabolism of glycosaminoglycans in injured
liver deserves more serious consideration than it has
previously received.
Apart from uncertainty as to the cellular origin of hepatic
glycosaminoglycans, the present study does not discrimin-
ate between the various subcellular compartments of pro-
teoglycans, in particular of proteoheparan sulfate. Since
hepatocellular proteoheparan sulfate resides predominant-
ly in the pericellular compartment (14-17, 34) it is likely
that D-galactosamine reduces markedly the content of
cell coat heparan sulfate. This conclusion is supported by
recent results demonstrating a significant reduction of
content and synthesis of an as yet unidentified, high
molecular weight, sulfated cell surface glycoprotein in
galactosamine-injured liver cell plasma membranes (34).
The pathobiochemical significance of the diminution of
cell surface proteoheparan sulfate remains to be deter-
mined. The proposed functions of this compound sug-
gest effects on the coordinated exchange and/or absorp-
tion of electrolytes, metabolites and fluids, on the ac-
cessibility of cell surface receptors, on the intercellular
recognition, adhesion and communication and on the
proliferating activity.
Further studies are concerned with the functional
meaning of reduced proteoheparan sulfate for the
mechanism of cell injury and with the question of
whether the observed changes are common to several
types of toxic liver cell injury. Furthermore, extended
time-course studies should show whether the greatly
stimulated synthesis of glycosaminoglycans in later
stages of injury represents initial molecular and cellular
events leading to the fibrotic transition of the organ, if
the hepatotoxic D-galactosamine is applied continuously
(36,37).
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